Ribo showcases new clinical data from its leading siRNA programs at ESC 2025, underscoring significant progress and achievements in advancing cardiovascular therapies

SuZhou Ribo life science Ltd. Co. and Ribocure Pharmaceuticals AB (Ribo) presented four key scientific findings at the 2025 European Society of Cardiology (ESC) Congress, underscoring significant progress in siRNA-based cardiovascular therapeutics pipeline. Ribo presented results from its ApoC3-silencing RBD5044 program`s Phase 1 clinical trial, which included single and multiple ascending dose studies (n=72 healthy […]